Real-world registry study of Dahuang Lidan tablet for nonalcoholic fatty liver disease

Phase 4, open-label, single-arm trial of Dahuang Lidan in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoints: ALT normalization or ≥30% reduction, Change in total cholesterol ratio and normalization rate and 1 more. Planned start Oct 2021; status: not yet recruiting.